Chinese startup begins first clinical trial using CRISPR to edit cells directly in the bone marrow

A little-known Chinese biotech startup has zipped ahead of US companies in one of the gene editing field’s most competitive races. YolTech Therapeutics announced Monday that it started a clinical trial ...